Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 19 Colorectal Neoplasms 11 Brain Neoplasms 7 Colonic Neoplasms 5 Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Rectal Neoplasms 2 Lung Neoplasms 2 Thyroid Neoplasms 1 Solid Tumor 1 Skin Neoplasms 1 Recurrence 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphatic Metastasis 1 Leukemia, Hairy Cell 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Astrocytoma 1

Interventions

apatinib 3 vistusertib 2 olaparib 2 camrelizumab 2 atezolizumab 2 Ipilimumab 2 Everolimus 2 trametinib 1 toripalimab 1 tilsotolimod 1 tazemetostat 1 tazarotene 1 spartalizumab 1 seviteronel 1 sargramostim 1 sacituzumab govitecan 1 rucaparib 1 roniciclib 1 romiplostim 1 pyrotinib 1 phosphorylethanolamine 1 pemigatinib 1 pembrolizumab 1 pazopanib 1 palbociclib 1 niraparib 1 magrolimab 1 lenvatinib 1 irinotecan sucrosofate 1 famitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor × encorafenib × Clear all

NCT03839342 2025-02-03

BEAVER

University Health Network, Toronto

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡